GHK-Cu 'beauty peptide' claims from @francielebianchi_dermato

What did @francielebianchi_dermato actually say?

Honestly, the transcript here is a mess. The audio appears to have been machine-translated or badly corrupted, producing gibberish like "the mosques of the U.S. Expyard" that has nothing to do with dermatology. What we can work with is the caption, which makes sweeping claims: a "daily injection" of GHK-Cu (also written GHK-Cu copper peptide in the hashtags) that "solves" flaccidity, acne, rejuvenation, and hair loss. The caption also frames this as a global phenomenon, using classic social proof pressure: "the whole world is using it" and "are you going to be left out?"

That framing matters. It is a marketing hook, not a clinical briefing. Without a legible transcript we cannot evaluate specific dosing, protocol, or mechanistic claims the creator may have made on camera. What we can evaluate is whether the caption's promises hold up to scrutiny.

Does the science back this up?

GHK-Cu has real, peer-reviewed support, but none of it justifies the "solves your problems" language in the caption. The evidence is promising and preliminary, not conclusive.

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) that has been studied for its effects on skin remodeling, wound healing, and anti-inflammatory signaling. Pickart and Margolina (2018, Cosmetics) reviewed decades of in vitro and animal data showing GHK-Cu stimulates collagen synthesis, activates antioxidant pathways, and modulates genes related to tissue repair. That is legitimate science.

For hair loss specifically, a small study by Perez-Sanchez et al. (2021, Journal of Cosmetic Dermatology) found topical GHK-Cu formulations improved hair density metrics in subjects with androgenetic alopecia, but the sample was small and the follow-up short. For acne, the evidence is thinner, mostly based on GHK-Cu's anti-inflammatory properties extrapolated from wound-healing models, not acne-specific trials. For "rejuvenation" as a broad anti-aging category, Pickart (2008, Journal of Biomaterials Science) documented gene expression changes in aged skin cells, but gene expression in a dish is not the same as clinical outcomes in patients.

Injected GHK-Cu specifically has almost no robust human clinical trial data. Most evidence is topical or in vitro.

What did they get wrong (or right)?

The caption gets the peptide identity right and the enthusiasm wrong. GHK-Cu is a real compound with a real scientific basis. Giving it that much credit is fair. But claiming a daily injection "resolves" flaccidity, acne, rejuvenation, and hair loss simultaneously is not supported by any trial we are aware of. No single peptide has demonstrated that breadth of clinical efficacy in humans under controlled conditions.

The phrase "the whole world is using it" is factually unsupportable. GHK-Cu remains an investigational compound in most injection contexts. In the United States, injectable GHK-Cu is not FDA-approved for any indication. In Brazil, where this creator appears to be based, peptide regulations differ, but that does not change the evidentiary standard for efficacy claims.

The "one injection solves multiple problems" framing is particularly problematic. It conflates separate physiological processes, skin laxity, sebaceous gland dysfunction, hair follicle cycling, and global aging, as if they share a single upstream switch. They do not. Presenting GHK-Cu as that switch is misleading regardless of how promising the underlying science is.

What should you actually know?

GHK-Cu is one of the better-studied peptides in the aesthetics space, and it is not snake oil. But the gap between "interesting mechanism" and "clinical solution" is where a lot of influencer content falls apart.

If you are considering GHK-Cu for any purpose, here is what the evidence actually supports. Topical GHK-Cu formulations have the most human data, particularly for skin texture and mild wound healing support. Injected protocols are being explored in compounding pharmacy contexts, but they lack the randomized controlled trial data you would expect before calling something a solution to anything.

Anyone recommending injectable peptides should be a licensed prescriber who has reviewed your health history. GHK-Cu can affect copper metabolism, and in people with Wilson's disease or other copper-handling disorders, that is not a trivial consideration. Side effects from injectable peptides are underreported in influencer content because most users who experience them do not post follow-up videos.

The social pressure framing, "are you going to be left out?" is a sales technique, not medical communication. Regulated telehealth platforms like FormBlends exist precisely because peptide therapy needs clinical oversight, not caption-driven FOMO.